VANCOUVER, Canada and HYDERABAD, India — January 31, 2026 — Mapmygenome, a pioneer in molecular diagnostics, genetic risk prediction, and microbiome research, is proud to announce the appointment of three globally recognized experts—Dr. B. Brett Finlay, Dr. Bill Mohn, and Mr. Mike Aicher—as Scientific and Strategic Advisors.
This strategic move strengthens Mapmygenome’s scientific foundation and accelerates its mission to provide accessible, actionable genomic data worldwide. By integrating leadership in microbiology, human health, and international business, the company is poised to redefine the genomics and diagnostics landscape.
-
Dr. B. Brett Finlay (Scientific Advisor): A Professor at the University of British Columbia and world-renowned microbiologist. Dr. Finlay is a pioneer in host-microbe interactions and infectious diseases, focusing on gut health. He will lead efforts to advance Mapmygenome’s microbiome-centered diagnostic innovations.
-
Dr. Bill Mohn (Scientific Advisor): A leading expert in microbial ecology and environmental genomics at the University of British Columbia. Dr. Mohn’s expertise in complex microbial communities and diagnostic assay development will enhance the company’s product innovation pipeline.
-
Mr. Mike Aicher (Strategic Advisor): A seasoned healthcare executive with decades of experience in operational leadership and commercialization. Mr. Aicher will guide Mapmygenome’s global market strategy and cultivate international partnerships to support scalable growth.
A Vision for the Future of Personalized Health
“We are delighted to welcome Dr. Finlay, Dr. Mohn, and Mr. Aicher to the Mapmygenome family,” said Anu Acharya, CEO of Mapmygenome & Microbiome Insights, Inc.. “Their collective expertise across science and global strategy is instrumental as we work toward making genetic information more accessible and actionable for improved health outcomes. This is a significant milestone in our journey as a frontrunner in personalized genomics.”
With the guidance of these advisors, Mapmygenome will focus on:
-
Next-Gen Diagnostics: Applying cutting-edge science to develop advanced wellness solutions.
-
Scientific Excellence: Maintaining the highest standards of validation and accuracy across all genomic services.
-
Global Reach: Navigating international markets to establish impactful partnerships.
About Mapmygenome
Mapmygenome is a pioneering personal genomics company delivering proactive and predictive health solutions that enable individuals to make informed, lifelong health decisions. By combining cutting-edge genomic science with advanced analytics, Mapmygenome translates complex genetic information into credible, science-backed, and actionable insights.
Its comprehensive portfolio includes Genomepatri, a comprehensive health and wellness genetic test; Epigenome, focused on ageing, longevity, and methylation insights; MapMyBiome, a gut microbiome test offering deep insights into digestive and metabolic health; MedicaMap, a pharmacogenomics solution that helps personalize medication response; and Heritage, an ancestry analysis that uncovers genetic origins and lineage. Together, these offerings empower individuals, clinicians, and wellness professionals to take a proactive approach to long-term health and well-being.
Media Contact:
Email: pr@mapmygenome.in
Phone: 1800 102 4595
Website: www.mapmygenome.in
